Related Experiment Video

Updated: Sep 30, 2026

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells
08:54

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells

Published on: July 20, 2014

Prostaglandin E2 increases growth and motility of colorectal carcinoma cells

H Sheng1, J Shao, M K Washington

  • 1Departments of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee 37232-2279, USA.

The Journal of Biological Chemistry
|March 30, 2001
PubMed

Insights

Nonsteroidal anti-inflammatory drugs reduce colorectal cancer risk. Prostaglandin E(2) (PGE(2)) may increase cancer cell motility by activating specific signaling pathways, potentially impacting invasive potential.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Chronic nonsteroidal anti-inflammatory drug (NSAID) use is linked to reduced colorectal cancer risk and mortality.
  • NSAIDs inhibit cyclooxygenase (COX) enzymes, crucial for prostaglandin synthesis.
  • Prostaglandin E(2) (PGE(2)) is a key product of COX activity implicated in various cellular processes.

Purpose of the Study:

  • To investigate the role of PGE(2) in human colorectal carcinoma cell behavior.
  • To elucidate the specific signaling pathways involved in PGE(2)-mediated effects on cancer cells.
  • To understand potential mechanisms by which NSAIDs might influence colorectal cancer progression.

Main Methods:

  • Treatment of LS-174 human colorectal carcinoma cells with PGE(2).
  • Analysis of changes in cell motility and morphology.
  • Investigation of the prostaglandin EP(4) receptor signaling pathway.
  • Assessment of phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) pathway activation.

Main Results:

  • PGE(2) treatment increased motility and altered cell shape in LS-174 cells.
  • The prostaglandin EP(4) receptor signaling pathway was implicated in mediating these effects.
  • PGE(2)-induced changes in cell motility and colony morphology were dependent on PI3K/Akt pathway activation.

Conclusions:

  • PGE(2) may enhance the invasive potential of colorectal carcinoma cells.
  • Activation of PI3K/Akt signaling is a key mechanism for PGE(2)-induced changes in cancer cell behavior.
  • These findings reveal novel intracellular signaling pathways regulated by prostaglandins in colorectal cancer.

More Related Videos

Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis09:28

Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis

Published on: May 12, 2019

Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer06:49

Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer

Published on: February 10, 2023

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...